GlobeNewsWire
02 Sept 2026, 10:37 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
An FDA advisory committee voted 9-3 that available evidence does not support the efficacy of Deramiocel for treating DMD-associated cardiomyopathy. — A negative advisory committee vote on a lead product candidate is a primary catalyst for total loss of valuation in biotech firms.
-0.90The FDA raised concerns regarding post-hoc changes to Capricor's statistical analysis plan and primary endpoint calculations conducted shortly before data unblinding. — Allegations of data manipulation or improper statistical shifts undermine the integrity of the clinical trials and the likelihood of FDA approval.
-0.80Capricor Therapeutics is facing a securities fraud class action lawsuit alleging misrepresentations regarding clinical data and the Biologics License Application (BLA). — Legal liabilities and fraud allegations create additional financial drain and governance risk on top of clinical failure.
-0.50Continue reading
6 related stories
Search tags
The FDA previously issued a Complete Response Letter stating that the Deramiocel application did not meet statutory requirements for substantial evidence of effectiveness. — A CRL is a formal rejection that indicates a high hurdle for future approval, necessitating expensive new trials.
-0.40Which stocks this story touches
The company is facing a securities fraud class action lawsuit following a massive stock drop and FDA concerns over clinical data integrity.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
8h ago
